Acurx Receives FDA Fast Track Designation for ACX-362E for the Treatment of C. difficile infection Jan 16, 2019
Acurx Pharmaceuticals to Enter Clinical Trials with First-In-Class Antibiotics to Treat Selected Gram-Positive Bacterial Infections Oct 4, 2018
FDA Grants QIDP Designation to Acurx’s Lead Antibiotic Product Candidate, ACX-362E for Clostridium Difficile Infection Jun 20, 2018
